Cagrilintide monotherapy at 4.5 mg weekly achieved 10.8% average weight loss over 26 weeks versus 3% with placebo in its Phase 2 dose-finding trial
Research reference: dosage ranges used in studies Scientific literature evaluating IGF-1 LR3 has explored a range of quantities and administration schedules depending on research objectives related to muscle hypertrophy, recovery, endurance, and metabolic health
(2002) conducted a placebo-controlled clinical trial showing GHK-Cu cream significantly improved skin laxity, clarity, and firmness while reducing fine lines and wrinkles versus placebo after 12 weeks
Flushing, headache, and transient blood pressure increases can also occur
If anything, we should be shortening the interval between injections, not making it longer
But the drugs also carry numerous potential side effects as well as increased pancreatitis risk